Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors.
Evaluation of the clinical benefits of adjuvant capecitabine monotherapy in elderly women with breast cancer: A retrospective study.
Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study.
The role of pharmacogenetics in capecitabine efficacy and toxicity.
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma.
Safety and efficacy of sunitinib in patients from Latin America: sub analysis of an expanded access trial in metastatic renal cell carcinoma.